This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Transplantation				
Organ transplant rejection	T cell immunoglobulin and mucin domain 1 (HAVCR1; TIM-1)	<p>Studies in mice suggest TIM-1 antibodies could help prevent transplant rejection. In a mouse model of pancreatic islet β cell transplant, anti-Tim-1 antibodies increased survival compared with control antibodies. Next steps include developing humanized anti-TIM-1 mAbs and exploring TIM-1 as a marker for isolating and enriching regulatory B cells with immunomodulatory properties.</p> <p>Celldex Therapeutics Inc.'s CDX-014 (CR014-vcMMAE), a toxin conjugated to a TIM-1 mAb, is in preclinical development for renal and ovarian cancer.</p> <p>SciBX 4(34); doi:10.1038/scibx.2011.973 Published online Sept. 1, 2011</p>	Patent pending; available for licensing	<p>Ding, Q. <i>et al.</i> <i>J. Clin. Invest.</i>; published online Aug. 8, 2011; doi:10.1172/JCI46274</p> <p>Contact: David M. Rothstein, The University of Pittsburgh School of Medicine, Pittsburgh, Pa. e-mail: rothsteind@upmc.edu</p>